Description du projet
Microscopie innovante assistée par logiciel pour le dépistage de la maladie de Lyme
La borréliose de Lyme est la zoonose la plus répandue en Europe. Si elle n’est pas diagnostiquée et traitée à un stade précoce, elle provoque des symptômes graves et potentiellement persistants, ce qui peut devenir une lourde charge pour le système de santé européen. Cependant, les tests sérologiques existants pour la maladie de Lyme sont très peu fiables lors des premiers stades. Le réactif et la méthode brevetés DualDur sont basés sur la détection directe de la bactérie et ne dépendent pas de la réponse immunitaire, ce qui permet un diagnostic précoce plus fiable, mais il s’agit d’une méthode de test supplémentaire dans les instituts de recherche. Le projet DualDur, financé par l’UE, validera une procédure d’essai innovante basée sur la microscopie assistée par logiciel, qui réduit de dix fois le temps nécessaire pour obtenir un résultat et nécessite moins de personnel, ce qui permettra de généraliser l’application de DualDur.
Objectif
Lyme borreliosis (LB) is the most common zoonotic disease in Europe with 650-850,000 estimated cases. Currently used serological tests for Lyme disease are highly unreliable in early stages of the infection, showing 17-40% sensitivity. If the disease is not diagnosed and treated early on; the infection often spreads to joints, the nervous system, and the heart causing severe and potentially persisting symptoms. Late stage, disseminated LB is a heavy burden on the patients in terms of quality of life and direct and indirect costs. It is also a significant burden on the European healthcare system: the majority of the €1 billion annual cost of the disease is associated with late stage LB. Our patented DualDur reagent and method enables a more reliable early diagnosis of Lyme disease than currently used serological methods, as it is based on direct detection of the bacteria and does not rely on the immune response. So far used as a supplementary testing method mainly at research institutes, in the present project we aim to validate a novel testing procedure based on software-aided microscopy. This will allow the wide-spread application of DualDur, as it improves time-to-result by 10 times, and decreases personnel need compared to our current procedure. Our improved reagent and software-aided testing enables us to provide the DualDur tests all over Europe through partnerships with medical laboratories. More reliable early diagnosis of Lyme disease will reduce the number of later stage cases significantly. This in turn will improve the quality of life of patients and reduce the financial burden of the disease, saving approximately € 330 million on healthcare costs in the first 5 years already. DualDur testing targets the €400 million European Lyme diagnostic market. We will be able to capture 5,1% of this growing market by 2024; representing an annual testing revenue of €23 million at our laboratory partners; and an annual turnover of close to €6 million to our company.
Champ scientifique
- natural sciencesbiological sciencesneurobiology
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicineimmunology
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health scienceshealth sciencespublic healthepidemiologyzoonosis
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
2011 BUDAKALASZ
Hongrie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.